Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Choice

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    556 result(s) found for: Choice. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005738-20 Sponsor Protocol Number: 0761-009 Start Date*: 2012-10-22
    Sponsor Name:Kyowa Hakko Kirin Pharma, Inc.
    Full Title: Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
    Medical condition: Treatment of patients with relapsed or refractory ATL
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001416 Adult T-cell lymphoma/leukaemia recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000277-72 Sponsor Protocol Number: ARRAY-162-311 Start Date*: 2013-09-18
    Sponsor Name:Array BioPharma Inc.
    Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or...
    Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002091-12 Sponsor Protocol Number: HUVE-19-CT-001 Start Date*: 2020-05-15
    Sponsor Name:HUVEPHARMA EOOD
    Full Title: Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and man...
    Medical condition: confirmed SARS-CoV-2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004493-26 Sponsor Protocol Number: D9670C00001 Start Date*: 2020-09-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose...
    Medical condition: HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002782-32 Sponsor Protocol Number: MK-3475-181 Start Date*: 2015-12-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma...
    Medical condition: Esophageal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) EE (Completed) PT (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) CZ (Completed) NL (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003998-34 Sponsor Protocol Number: CEGF816A2302 Start Date*: 2018-06-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Randomized, Open-label, Phase III Study of single agent Nazartinib Versus Investigator’s choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients with locally advanced or metastatic No...
    Medical condition: Advanced Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004008-16 Sponsor Protocol Number: 20190172 Start Date*: 2022-01-26
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Pr...
    Medical condition: Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Restarted) GR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003291-38 Sponsor Protocol Number: CA184-243 Start Date*: 2013-03-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with ...
    Medical condition: Advanced Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018050-34 Sponsor Protocol Number: V1.0,18.08.2009 Start Date*: 2010-06-04
    Sponsor Name:Medizinische Universität Wien,Univ.Klinik f.Anästhesie, Intensivmedizin und Schmerztherapie
    Full Title: Perioperative fluid management in patients receiving cadaveric renal transplants – Effects of normal saline versus balanced infusates on the incidence of electrolyte and acid-base disturbances
    Medical condition: patients receiving cadaveric renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000371-39 Sponsor Protocol Number: MK-4280A-008 Start Date*: 2022-08-31
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractor...
    Medical condition: PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002569-32 Sponsor Protocol Number: izoz/0025 Start Date*: 2015-06-12
    Sponsor Name:Academic Medical Center
    Full Title: Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project
    Medical condition: prevention of HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005838-22 Sponsor Protocol Number: CLIO Start Date*: 2016-07-22
    Sponsor Name:UZLeuven
    Full Title: Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in Ovarian Cancer (CLIO). Establishing the value of a ctDNA-based HRD assay for predicting olaparib response in women with relapsed ovar...
    Medical condition: platinum-sensitive and platinum-resistant relapsed ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003153-18 Sponsor Protocol Number: IMCgp100-202 Start Date*: 2017-08-25
    Sponsor Name:Immunocore Limited
    Full Title: A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced U...
    Medical condition: Uveal Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Trial now transitioned) NL (Completed) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003389-25 Sponsor Protocol Number: CC-5013-MCL-002 Start Date*: 2011-04-11
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
    Medical condition: Patients with mantle cell lymphoma are refractory to their regimen or have relapsed once or up to three times.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) DK (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023066-52 Sponsor Protocol Number: OMB114242 Start Date*: 2011-02-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter study investigating the safety and efficacy of ofatumumab therapy versus physicians' choice in patients with bulky fludarabine refractory chronic lymphocytic leukaemia (CLL)
    Medical condition: Chronic lymphocytic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) HU (Completed) FR (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SK (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004505-32 Sponsor Protocol Number: COMB157G3301 Start Date*: 2021-06-09
    Sponsor Name:Novartis Pharma AG
    Full Title: An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician’s choi...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003809-60 Sponsor Protocol Number: XPORT-MF-035 Start Date*: 2021-10-08
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Trial now transitioned) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-014445-80 Sponsor Protocol Number: CP4055-306 Start Date*: 2010-06-23
    Sponsor Name:Clavis Pharma
    Full Title: A Randomised Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukaemia
    Medical condition: Late Stage Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066764 Acute myeloid leukaemia progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) ES (Ongoing) BE (Completed) PL (Completed) IT (Ongoing) GB (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005137-20 Sponsor Protocol Number: D0819C00003 Start Date*: 2014-04-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Chemotherapy in the Treatment of Metastatic B...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) IT (Completed) CZ (Completed) ES (Ongoing) BG (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003770-85 Sponsor Protocol Number: DKFZ-2019-007 Start Date*: 2020-08-20
    Sponsor Name:German Cancer Research Center (DKFZ)
    Full Title: Effect of low-dose acetylsalicylic acid on early detection of advanced colorectal neoplasms
    Medical condition: Screening for advanced colorectal neoplasms. Male individuals aged 40 to 79 years scheduled for screening colonscopy and no use of acetylsalicylic acid (or other drugs with an effect on the blood ...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 01:05:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA